Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Stock Watch: Contrasting Novartis And J&J Stock Movements Defy Explanation

Strong Dollar Should Not Be Overlooked In Q2 Results

Jul 26 2022

• By Andy Smith

Andy Smith — ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Related Content

HEC Pharm Wins Key Reversal In US Gilenya Dosing Patent Fight

Jun 22 2022

Leqvio Sales Still Lag But Novartis Is Playing The Long Game

Jul 20 2022

J&J: Inflationary Pressures ‘Here To Stay’ With Impact Likely Into 2023

Jul 19 2022

Novartis Finance Chief Rules Out Large M&A

Jul 19 2022

The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall

Apr 04 2022

Related Companies

Novartis AG

Roche Holding AG

Johnson & Johnson

AstraZeneca PLC

Additional Topics

Sales & Earnings Commercial Companies Business Strategies Stock Watch BioPharmaceutical

More from Stock Watch

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window